Rigel Pharmaceuticals (FRA:RI2) Minority Interest: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RI2 Rigel Pharmaceuticals Inc FRA:RI2
26 GF Score
Price €34.88
GF Value €23.39
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Rigel Pharmaceuticals Minority Interest?

Rigel Pharmaceuticals FRA:RI2 -0.46% 26 Minority Interest is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:RI2 with a GF Score™ of 26/100 and a GF Value™ of €23.39 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Rigel Pharmaceuticals's minority interest for the quarter that ended in Mar. 2026 was €0.00 Mil.

Rigel Pharmaceuticals Minority Interest Historical Data

* Premium members only.

The historical data trend for Rigel Pharmaceuticals's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rigel Pharmaceuticals Minority Interest Chart

Rigel Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rigel Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:RI2
26GF Score
Rigel Pharmaceuticals Inc FRA:RI2
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rigel Pharmaceuticals Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of €0.00 Mil mean?
Rigel Pharmaceuticals (FRA:RI2) has a Minority Interest of €0.00 Mil as of Mar. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Rigel Pharmaceuticals.
Is Rigel Pharmaceuticals' Minority Interest too high?
Rigel Pharmaceuticals' current Minority Interest is €0.00 Mil. Overall, Rigel Pharmaceuticals has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Minority Interest compare to CADL and IMMX?
Rigel Pharmaceuticals' Minority Interest of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Rigel Pharmaceuticals. Rigel Pharmaceuticals's current Minority Interest is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Rigel Pharmaceuticals (FRA:RI2) is currently considered Significantly Overvalued. The stock's GF Value™ is €23.39, compared to a current price of €34.88 — trading 49.1% above its estimated fair value. The current Minority Interest is €0.00 Mil. Rigel Pharmaceuticals' overall GF Score™ is 26/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Minority Interest is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?

Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued. The current stock price of €34.88 is trading 49.1% above its estimated GF Value™ of €23.39. GuruFocus considers Rigel Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:RI2:

  • Minority Interest: €0.00 Mil
  • GF Value™: €23.39 vs. price of €34.88 (49.1% above fair value)
  • GF Score™: 26/100 with 7 warning signs

No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rigel Pharmaceuticals Business Description

Other Exchanges RIGL:USA
Address 611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
26GF Score

Get the complete analysis for FRA:RI2

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€34.88
Price
€23.39
GF Value